American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: Editor-in-chief: Apply for this position
Open Access
Journal Browser
American Journal of Medical Case Reports. 2019, 7(1), 5-8
DOI: 10.12691/ajmcr-7-1-2
Open AccessCase Report

A Rare Case of HIV-Induced Inflammatory Demyelinating Polyneuropathy

Abin Sajan BS1, Soombal Zahid DO2, Jordan Stumph MD2, Daniel Griepp BE1, Sami Saba MD2, Nazish Ilyas MD2 and Isabel M. Mc Farlane MD1,

1Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Avenue Brooklyn, NY 11203 (718) 270-2030

2Department of Medicine, Lenox Hill Hospital, Department of Medicine, 100 E 77th Street New York, NY 10075 (212) 434-2000

Pub. Date: January 21, 2019

Cite this paper:
Abin Sajan BS, Soombal Zahid DO, Jordan Stumph MD, Daniel Griepp BE, Sami Saba MD, Nazish Ilyas MD and Isabel M. Mc Farlane MD. A Rare Case of HIV-Induced Inflammatory Demyelinating Polyneuropathy. American Journal of Medical Case Reports. 2019; 7(1):5-8. doi: 10.12691/ajmcr-7-1-2


Background: Acute inflammatory demyelinating polyneuropathy (AIDP) is an uncommon form of neuropathy in HIV-infected patients that can cause pain, sensory disturbance, and motor weakness. Case presentation: A 23-year-old African American male with past medical history of Guillain-Barre Syndrome (GBS), Lyme disease, and sexually transmitted infections including syphilis and chlamydia presented with acute back pain radiating to bilateral lower extremities with worsening right foot weakness for four days. Cerebrospinal fluid (CSF) studies including meningoencephalitis panel were negative as well as blood tests for Lyme disease and HIV antibody testing. Patient was initially treated with penicillin for positive treponemal serology but without improvement in lower extremity weakness. Electromyogram showed evidence of early demyelinating motor polyneuropathy. Four days after presentation, repeat HIV antibody testing returned positive. Recurrent AIDP in this case was suspected to be secondary to acute HIV infection, and highly active antiretroviral therapy (HAART) was administered along with intravenous immunoglobulin (IVIG). Muscle strength improved with therapy and patient was expected to have continued improvement with intensive rehabilitation after discharge. Conclusion: Acute inflammatory demyelinating polyneuropathy (AIDP) tends to present early in course of HIV infection. Therefore, HIV testing should be obtained in individuals presenting with new neurological deficits. Our patient received HAART therapy, in addition to the traditional modalities to manage AIDP, which led to a substantial recovery of his sensorimotor function.

human immunodeficiency virus acute inflammatory demyelinating polyneuropathy Guillain-Barre syndrome intravenous immunoglobulin peripheral neuropathy chronic inflammatory demyelinating polyneuropathy highly active antiretroviral therapy

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Arts, E.J. and D.J. Hazuda, HIV-1 antiretroviral drug therapy. Cold Spring Harbor perspectives in medicine, 2012. 2(4): p. a007161-a007161.
[2]  Bilgrami, M. and P. O'Keefe, Neurologic diseases in HIV-infected patients. Handb Clin Neurol, 2014. 121: p. 1321-44.
[3]  Gelman, B.B., Neuropathology of HAND With Suppressive Antiretroviral Therapy: Encephalitis and Neurodegeneration Reconsidered. Current HIV/AIDS reports, 2015. 12(2): p. 272-279.
[4]  Kolson, D., Neurologic Complications in Persons With HIV Infection in the Era of Antiretroviral Therapy. Topics in antiviral medicine, 2017. 25(3): p. 97-101.
[5]  Saylor, D., et al., HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment. Nature reviews. Neurology, 2016. 12(5): p. 309-309.
[6]  Wulff, E.A., A.K. Wang, and D.M. Simpson, HIV-Associated Peripheral Neuropathy. Drugs, 2000. 59(6): p. 1251-1260.
[7]  Moodley, K., P.L.A. Bill, and V.B. Patel, A comparative study of CIDP in a cohort of HIV-infected and HIV-uninfected patients. Neurology(R) neuroimmunology & neuroinflammation, 2016. 4(2): p. e315-e315.
[8]  Shepherd, S.J., et al., HIV positive patient with GBS-like syndrome. JMM Case Rep, 2017. 4(8): p. e005107.
[9]  Hagberg, L., et al., Guillain-Barré Syndrome as an Early Manifestation of HIV Central Nervous System Infection. Scandinavian Journal of Infectious Diseases, 1986. 18(6): p. 591-592.
[10]  Parry, G.J., Peripheral neuropathies associated with human immunodeficiency virus infection. Annals of Neurology, 1988. 23(S1): p. S49-S53.
[11]  Willison, H.J., B.C. Jacobs, and P.A. van Doorn, Guillain-Barre syndrome. The Lancet, 2016. 388(10045): p. 717-727.
[12]  Dimachkie, M.M. and R.J. Barohn, Guillain-Barré syndrome and variants. Neurologic clinics, 2013. 31(2): p. 491-510.
[13]  Pontali, E., et al., Guillain-Barre Syndrome with Fatal Outcome during HIV-1-Seroconversion: A Case Report. Case Reports in Infectious Diseases, 2011. 2011: p. 4.
[14]  Sloan, D.J., et al., Human immunodeficiency virus seroconversion presenting with acute inflammatory demyelinating polyneuropathy: a case report. J Med Case Rep, 2008. 2: p. 370.
[15]  Petratos, S., et al., Antibodies against peripheral myelin glycolipids in people with HIV infection. Immunol Cell Biol, 1998. 76(6): p. 535-41.
[16]  Rosca, E.C., O. Rosca, and M. Simu, Intravenous immunoglobulin treatment in a HIV-1 positive patient with Guillain-Barré syndrome. International Immunopharmacology, 2015. 29(2): p. 964-965.
[17]  Köller, H., et al., Chronic Inflammatory Demyelinating Polyneuropathy. New England Journal of Medicine, 2005. 352(13): p. 1343-1356.
[18]  Mathey, E.K., et al., Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. Journal of neurology, neurosurgery, and psychiatry, 2015. 86(9): p. 973-985.
[19]  Ramos Ttito, A.P., et al., Chronic inflammatory demyelinating polyneuropathy associated with HIV and Neurosyphilis coinfection. Journal of the Neurological Sciences, 2017. 381: p. 830.
[20]  Hiraga, A., et al., Recovery patterns and long term prognosis for axonal Guillain–Barré syndrome. Journal of Neurology, Neurosurgery & Psychiatry, 2005. 76(5): p. 719.
[21]  Meena, A.K., S.V. Khadilkar, and J.M.K. Murthy, Treatment guidelines for Guillain-Barré Syndrome. Annals of Indian Academy of Neurology, 2011. 14(Suppl 1): p. S73-S81.
[22]  Harms, M., Inpatient management of guillain-barré syndrome. The Neurohospitalist, 2011. 1(2): p. 78-84.
[23]  Brannagan, T.H., 3rd and Y. Zhou, HIV-associated Guillain-Barre syndrome. J Neurol Sci, 2003. 208(1-2): p. 39-42.
[24]  Kuitwaard, K., et al., Recurrent Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry, 2009. 80(1): p. 56-9.
[25]  Makela, P., et al., Recurrent Guillain-Barre syndrome as a complication of immune reconstitution in HIV. J Infect, 2002. 44(1): p. 47-9.